Animal Model and Therapeutics Evaluation Core
Mission of the Core
The purpose of the Animal Model and Therapeutics Evaluation Core (AMTEC) is to enhance the peer reviewed funded research activities of Karmanos Cancer Institute members whose research needs involve the use of animal models. Our goal is to provide expert scientific consultation, technical expertise and access to a wide breadth of relevant tumor models and associated animal-related services.
The Animal Model and Therapeutics Evaluation Core is supported, in part, by NIH Center grant P30 CA022453 to the Karmanos Cancer Institute at Wayne State University.
Core Services Available
- Animal Study Technical Support
- Tumor Models and Cell Lines (Mouse and Human – Syngeneic, Transgenic, GEMM, Xenograft and PDX)
- In Vivo Orthotopic Tumor and Metastasis Models
- In Vivo Therapeutic Evaluation: Consultation, Study Design, Implementation and Analysis
- In Vivo Training/Teaching for researchers, staff and students
- Consultation and Assistance: Grant, manuscript and IACUC submissions
- In Vivo Study Sampling: pK analysis treatment and time point collections; treatment and harvest of tumor and/or tissue specimens at endpoint or during Rx regimens for further analyses (e.g. to BCS, Proteomics, Pharmacology Cores as well as for genomics, metabolomics and veterinary pathological examination).
Resources
- Two ultracold units (-80⁰C & -150⁰C) connected to the Public Safety monitoring system
- New dedicated cell culture room w/BSL2 laminar flow hood
- Table top refrigerated centrifuge
- Two Panasonic incubators equipped with germicidal & UV sterilization
- New BSL2 flow hood (animal suite)
- Eight liquid nitrogen dewars
- Somno suite and SurgiSuite surgical platforms for surgical procedures
- Techniplast environmental chamber
- Excelsior AS Tissue Processor and HistoStar Instrument Embedding Center
Animal Model and Therapeutics Evaluation Core Selected Publications
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemother Pharmacol 2013;71:999-1011. PMCID: PMC3749077
Authors: Cherian C, Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Gangjee A, Matherly LH.
Functional Loss of the Reduced Folate Carrier Enhances the Antitumor Activities of Novel Antifolates with Selective Uptake by the Proton-coupled Folate Transporter. Mol Pharmacol 2012;82:591-600. PMCID: PMC3463226
Authors: Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH.
Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biol Ther 2012;13:1042-6. PMCID: PMC3461811
Authors: Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W, Wu GS.
Antagonists of anaphase promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis. J Biol Chem 2011;286:38000-17. PMCID: PMC3207393
Authors: Puliyappadamba VT, Wu W, Bevis D, Zhang L, Polin L, Kilkuskie R, Finley RL, Larsen SD, Levi E, Miller FR, Wali A, Rishi AK.
Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One 2012;7:e41214. PMCID: PMC3422308
Authors: Yang H, Wang Y, Cheryan VT, Wu W, Cui CQ, Polin LA, Pass HI, Dou QP, Rishi AK, Wali A.
Contact
Lisa Polin, Ph.D.
Director, Animal Model and Therapeutics Evaluation Core
polinl@karmanos.org
Sijana Dzinic, Ph.D.
Assistant Director, Animal Model and Therapeutics Evaluation Core
dzinics@karmanos.org